Staging ::: VER CORREOS
España
Acceder
  1. Inicio
  2. Perfil de barth
  3. Participaciones

Participaciones del usuario barth - Bolsa

Foro:
SOS-Deoleo (15) | Bolsa (1196)
barth 03/07/25 19:27
Ha respondido al tema Farmas USA
Hasta en eso te pedimos ayuda jeje , muchas gracias investing !!! 
barth 03/07/25 10:06
Ha respondido al tema Farmas USA
jeje yo ya me pierdo , entiendo que las que estan mejor son las del cuadro superior derecho ?
barth 24/06/25 19:10
Ha respondido al tema Farmas USA
yo en las caidas fui comprando mas caribou ya las tengo en verde rico , espero que las bajadas de tipos lleguen pronto y si no les da x decir nada de las bios , deberian volar CRBU
barth 23/06/25 21:38
Ha respondido al tema Farmas USA
hoy compre fuerte novo me parece que esta a un precio muy bueno, su informe no me parece nada malo , hacen billetes como pocas, bien gestionada  y ya hasta el divi es interesante NVO
barth 23/06/25 21:34
Ha respondido al tema Otras Aventuras de los Farmas USA
yo compre hoy mas google a 164  , estos precios son bien ricos GOOG
barth 19/06/25 17:59
Ha respondido al tema Farmas USA
dos gigantes con esas se duerne tranquilo en verano , suerte !!BABA , PFE
barth 16/06/25 16:36
Ha respondido al tema Otras Aventuras de los Farmas USA
yo compré 3D system a 1,70 la semana pasada y mira hoy  y las oklo me van a hacer de hablar con hacienda ya muyyy fuerte este año , ya mas del 100% ufff ni se como aguanté tanto DDD y OKLO 
barth 16/06/25 16:33
Ha respondido al tema Farmas USA
iba a poner noticias de una demanda colectiva contra IOVA pero me censura Rankia el comentario , le crecen los enanos , yo meti mas con las caidas , esperemos que sea humo y esto tire fuerte o la compren a buen precio por su calidad de pipeline IOVA 
barth 16/06/25 16:29
Ha respondido al tema Farmas USA
 IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)  IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was  NEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws.If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities.   The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al., No. 25-cv-04177.Why was Iovance Sued for Securities Fraud?Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company’s authorized treatment centers (“ATCs”).As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance’s ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs.The Stock Declines as the Truth is RevealedOn May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was “revising full-year 2025 revenue guidance.” The Company blamed “recent launch dynamics,” including slow “treatment timelines for new ATCs” and “the variable pace at which ATCs began treating patients,” which “differs from center to center.” Iovance also blamed the poor results on high “patient drop-off” due to inadequate “patient selection” for treatment.On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025.Click here if you suffered losses: https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.What Can You Do?If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm.All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. 
barth 02/06/25 16:03
Ha respondido al tema Seguimiento de Rio Tinto (RIO)
buenas !! en el xetra te deja la opcion de coger el dividendo en acciones ? Rio tinto